Brief: Arcellx Doses First Patient In Phase 1 Trial Evaluating Treatment Of Relapsed Or Refractory Multiple Myeloma
10/05/2022 21:02
May 10 (Reuters) - Arcellx Inc ACLX.O :
* ARCELLX ANNOUNCES DOSING OF FIRST PATIENT IN ITS PHASE 1
CLINICAL TRIAL EVALUATING ACLX-001, THE FIRST THERAPEUTIC IN THE
DOSABLE AND CONTROLLABLE ARC-SPARX PLATFORM, FOR THE TREATMENT
OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Source text for Eikon: ID:nPn3cJCKPa
Further company coverage: ACLX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcellx
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 02:18 PM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Brief: Gilead Extends Tender Offer To Acquire Arcellx
U.S. RESEARCH ROUNDUP-Arcellx, Costar Group, Magnite